ClinicalTrials.Veeva

Menu

iTBS for Acute Ischemic Stroke After Thrombectomy

Y

Yi Yang

Status

Enrolling

Conditions

Ischemic Stroke

Treatments

Device: intermittent theta burst stimulation
Device: sham intermittent theta burst stimulation

Study type

Interventional

Funder types

Other

Identifiers

NCT06941961
iTBS-ACT

Details and patient eligibility

About

The goal of this randomized, single-blind, parallel-controlled clinical trial is to evaluate the efficacy and safety of intermittent theta burst stimulation (iTBS) as an adjunctive therapy for acute anterior circulation ischemic stroke patients who have undergone successful mechanical thrombectomy (MT). The study population includes adults aged 18-85 with NIHSS scores 5-25 post-MT and eTICI≥2b reperfusion.

Enrollment

178 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

    1. Age 18-85 years, regardless of gender.
    1. Acute ischemic stroke caused by occlusion of the anterior circulation large vessels (internal carotid artery, M1 or M2 segment of the middle cerebral artery), verified by CTA or DSA.
    1. Mechanical thrombectomy (MT) performed within 24 hours of symptom onset.
    1. Successful Reperfusion: Post-MT eTICI score ≥ 2b.
    1. NIHSS score 5-25 at 24 hours post-MT, with ≥2 points in at least one limb.

Exclusion criteria

    1. Pre-stroke modified Rankin Scale (mRS) score ≥2.
    1. PH2-type intracranial hemorrhage on brain CT post-MT.
    1. Patients who underwent intracranial stent placement during MT.
    1. Contraindications to iTBS: History of epilepsy or seizures, implanted cardiac pacemakers, cochlear implants, or other electronic/magnetic-sensitive devices.
    1. Severe consciousness impairment, cognitive dysfunction, or psychiatric disorders preventing compliance with iTBS.
    1. Expected survival <3 months due to other medical conditions or inability to complete follow-up for any reason.
    1. Participation in another interventional study.
    1. Any other condition deemed unsuitable for enrollment by the investigator.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

178 participants in 2 patient groups

iTBS
Active Comparator group
Description:
Patients are treated with intermittent theta burst stimulation (iTBS).
Treatment:
Device: intermittent theta burst stimulation
sham-iTBS
Sham Comparator group
Description:
Patients are treated with sham intermittent theta burst stimulation (sham-iTBS).
Treatment:
Device: sham intermittent theta burst stimulation

Trial contacts and locations

1

Loading...

Central trial contact

Yi Yang, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems